DIANAMED 10 (Methandienone) is a pharmacological drug belonging to the class of androgens and anabolic steroids (AAS). The main action of any steroid in the body is to increase the production of the male sex hormone testosterone. As a result, anabolic processes are activated, weight and physical parameters increase.

The term “cachexia” comes from the Greek words “kakos” and “hexis,” which mean “bad condition.” Cachexia is a “wasting” disorder that occurs because of the depletion of adipose tissue and muscle mass in someone who is not actively trying to lose weight. They lose weight because they eat less due to a variety of reasons. This condition affects people who are in the late stages of serious diseases like cancer, HIV or AIDS, coeliac disease, chronic obstructive pulmonary disease (COPD), kidney disease, and congestive heart failure (CHF). Other diseases also include multiple sclerosis, rheumatoid arthritis, tuberculosis, familial amyloid polyneuropathy, multiple system atrophy, mercury poisoning (acrodynia), Crohn's disease, untreated/severe type 1 diabetes mellitus, anorexia nervosa, hyperthyroidism, and hormonal deficiency.

Cachexia is associated with extreme loss of weight, muscle atrophy, fatigue, weakness and significant loss of appetite. At the same time, their metabolism changes, and this causes their body to break down too much muscle. Such factors as inflammation and substances created by tumors can affect appetite and cause the body to burn calories more quickly than usual.

Researchers state that cachexia is the body’s response to fighting disease. To get more energy necessary to fuel the brain when nutritional stores are low, the body breaks down muscle and fat. A person suffering from cachexia doesn't simply lose weight. That can be a very dangerous condition, as they get so weak and frail that their body becomes vulnerable to infections. It is a positive risk factor for death, meaning if the person has cachexia, the chance to die from their underlying condition is increased dramatically.

Cachexia physically weakens patients to a state of immobility stemming from the loss of appetite, asthenia, and anemia, at the same time the response to standard treatment is usually poor. Cachexia includes sarcopenia as a part of its pathology.

Although there is no specific treatment or way to reverse cachexia, DIANAMED 10 (Methandienone) is among effective treatments of AIDS-related cachexia. Current therapy for cachexia is aimed to achieve the main goal of treatment - to improve symptoms and quality of life. The thing is that simply getting more nutrition or calories isn’t enough to reverse cachexia.

DIANAMED 10 (Methandienone) is indicated for the treatment of severe cachexia resulting from AIDS. Also, DIANAMED 10 (Methandienone) may be utilized for treatment of cachexia of various origin, hereditary angioedema, asthenia, convalescence after serious injuries, operations, burns, in the preoperative and postoperative period, as well as after irradiation and infectious diseases, kidney and adrenal insufficiency, toxic goiter, muscular dystrophy, osteoporosis and delayed bone callus after fractures, myopathy and progressive muscular dystrophy. Additionally, DIANAMED 10 (Methandienone) is effectively used as part of complex therapy for tuberculosis, osteomyelitis, asthma, and hepatitis.

Anemia is a very important and common problem in cancer patients. There are many different forms of anemia, each with its cause. Anemia in cancer patients is often the result of both cancer itself and chemotherapy. Moreover, anemia is a common complication for almost all cancer patients treated with chemotherapeutic agents. Anemia can be temporary or long term, and it can range from mild to severe. Several factors play a role in whether a patient will develop anemia, such as the type of the received chemotherapy, the stage of cancer and patients overall health condition. Patients with anemia experience many unwanted symptoms such as weakness, fatigue, tiredness, shortness of breath and reduced tolerance to activity.

Anemia in cancer patients is quite common and can compromise the delivery of sufficient amounts of oxygen to all cells, including tumor cells. This condition can worsen the results of radiotherapy and chemotherapy and have negative impacts on quality of life and overall survival prognosis. This is so because low tissue oxygenation is also associated with reduced sensitivity of tumors to radiation and some forms of chemotherapy, anemia is contributing to the progression of cancer.

This article focuses on the treatment of anemia with DECAMED 250 (Nandrolone Decanoate) in patients suffering from cancer. Treatments for anemia can range from taking supplements to undergoing medical procedures. DECAMED 250 (Nandrolone Decanoate) is an anabolic steroid that is effectively used in the treatment of anemia in renal failure. DECAMED 250 (Nandrolone Decanoate) is considered one of the least virilizing preparations.

Recent research was done to see if DECAMED 250 (Nandrolone Decanoate) could be safely used in the treatment of anemia in cancer patients. Methods: twenty five cancer patients, 8 males and 17 females, median age was 58 years (range 33-65), with Hemoglobin level < 10 g/dL, performance status (PS) 0-2, adequate hepatic functions, normal serum calcium and prothrombin time, life expectancy of at least 12 weeks, recovery from all acute toxicities of prior therapies were eligible. Weekly dosage of DECAMED 250 (Nandrolone Decanoate) was given intramuscularly 200 mg in male and 100 mg in female patients for 12 weeks. 13 patients had lung cancer, 5 had cholangiocarcinoma and 1 each patient had bladder, breast, stomach, rectum, colon, small cell cancer of orbit, giant cell tumor with lung metastasis. Twelve patients (48%) were responders (Hb increase ≥ 1 g/dL), by 24% respond within 4 weeks and 24% respond within 8 weeks. Four patients (12%) did not complete the study because they needed a blood transfusion. The common results were smooth skin (92%) weight gain (84%),mild erythema of face (64%), increased appetite (52%), mood swing (40%), edema (32%) and hoarseness (28%), fatigue (24%), myalgia/arthralgia (24%), increased LDL-cholesterol (20%), increased fasting blood glucose (16%), increased serum creatinine (16%), and penile erection(12%).

This research has indicated that DECAMED 250 (Nandrolone Decanoate) appears to be a safe and feasible drug which can be used for the treatment of anemia in cancer patients. In the future, this anabolic steroid could be a choice of treatment of anemia.

DECAMED PP 100 (Nandrolone Phenylpropionate) is an injectable form of the anabolic steroid nandrolone, which was the first Nandrolone compound to ever be sold by Organon back in the 1950s. DECAMED PP 100 (Nandrolone Phenylpropionate) is often confused with DECAMED 250 (Nandrolone Decanoate). While these two compounds have common similarities, they are different compounds. Although DECAMED 250 (Nandrolone Decanoate) is more popular and is commonly used, the Phenylpropionate version is also still used with some regularity.

DECAMED PP 100 (Nandrolone Phenylpropionate) is an anabolic steroid that is enhancing anabolic and reducing androgenic activity when compared to testosterone. The esterification of the 17-beta-hydroxyl group increases the duration of the action of nandrolone. Nandrolone esters in oil injected intramuscularly are absorbed slowly from the lipid phase.

Initially, nandrolone was very effectively used in the treatment of many different diseases and conditions. For example, nandrolone can be beneficial for osteoporosis, breast cancer, burns, injury healing, and growth deficiency in children. Also, DECAMED PP 100 (Nandrolone Phenylpropionate) has been widely used in the treatment of various chronic diseases. For instance, the drug has been helping HIV/AIDS patients regain wasted muscles. Despite this fact, over the years, the US FDA has been shortening the list of diseases where nandrolone is allowed for treatment. Nowadays, nandrolone is only prescribed to treat anemic patients and those suffering wasting syndromes, especially HIV/AIDS-related. DECAMED PP 100 (Nandrolone Phenylpropionate) , NPP for short, also helps HIV/AIDS patients to regain their weight and muscles. HIV/AIDS is the illnesses that lead to massive weight loss. With the help of NPP, patients can be sure that they will regain their weight since the drug is known for helping users gain some pounds within the shortest time possible. Additionally, DECAMED PP 100 (Nandrolone Phenylpropionate) also stimulates the production of red blood cells which, in turn, is increasing the blood levels in the body as well as increasing the supply of nutrients in various parts of the body. Another medical benefit that is often reported by nandrolone users – it greatly improves the immune system, and it is therefore often employed as a supporting agent.

DECAMED PP 100 (Nandrolone Phenylpropionate) can be effectively used for the treatment of osteoporosis. Patients with osteoporosis can have significant benefits from this fantastic nandrolone version. In several human trials, nandrolone has been shown to positively influence calcium metabolism and to increase bone mass in osteoporosis. For medical use, the typical dose of DECAMED PP 100 (Nandrolone Phenylpropionate) is between 50 mg and 100 mg weekly. For females, the medical dose would be no more than 50 mg per week.

Induction of Ovulation with (CLOMIMED 50) Clomiphene Citrate

The most common causes of reproductive failure in subfertile and infertile couples are ovulatory dysfunction. Since the very first clinical trial was published in 1961, (CLOMIMED 50) Clomiphene Citrate remains the most commonly prescribed ovulation-inducing medication and is the front-line therapy in the largest majority of anovulatory infertile women. Its use quickly expanded to other empiric indications, such as luteal phase defect and the enhancement of fecundity in case of unexplained infertility. Although a lot of other solutions appeared in recent years, (CLOMIMED 50) Clomiphene Citrate is still widely used.

Initial studies of the therapeutic potential of (CLOMIMED 50) Clomiphene Citrate focused on its adverse effects on fertility in animals. In 1961, the first clinical trial for ovulation induction in women was performed. Briefly after, the second trial reported successful induction of ovulation in nearly 80% of a group of amenorrheic anovulatory women, half of whom successfully conceived during treatment. Today, despite the advent of modern immunoassays for steroid hormones, results of (CLOMIMED 50) Clomiphene Citrate treatment remained the same and have not changed. Nowadays, such advances as ultrasound technology for cycle monitoring and the introduction of commercial ovulation predictor kits (OPK) allow accurate identification of the midcycle luteinizing hormone (LH) surge. Tracking the surge in luteinizing hormone levels can help to plan intercourse and increase the chances of becoming pregnant.

Indications for treatment with (CLOMIMED 50) Clomiphene Citrate

There are three main indications for (CLOMIMED 50) Clomiphene Citrate:

• Anovulation.

There are many and varied causes of anovulation. The right treatment should be directed at correcting the underlying cause because the correct diagnosis may suggest specific treatment and many of these conditions may have longer-term health consequences. In most cases, the immediate cause of anovulation cannot be confidently defined. Following health problems may be identified: thyroid disease, pituitary tumors, eating disorders, extremes of weight loss and exercise, hyperprolactinemia, polycystic ovary syndrome, and obesity. (CLOMIMED 50) Clomiphene Citrate is the initial treatment of choice for most anovulatory or oligo-ovulatory infertile women who are euthyroid and euprolactinemic and have normal circulating levels of estrogen hormone.

• Luteal Phase Deficiency

Luteal phase deficiency has been defined as a condition in which the ovarian secretion of progesterone is not sufficient to maintain a functional secretory endometrium that supports embryo implantation and growth of early pregnancy. Given that the corpus luteum derives from the follicle that ovulates, its functional capacity is, at least in part, dependent on the quality of preovulatory follicle development. Progesterone levels are typically higher after (CLOMIMED 50) Clomiphene Citrate treatment than in spontaneous cycles, reflecting improved preovulatory follicle and corpus luteum development and/or the hormone production from more than one corpus luteum.

• Unexplained Infertility

That happens, that sometimes the reasons for infertility remains unexplained even after a careful and thorough evaluation. Treatment with (CLOMIMED 50) Clomiphene Citrate can be a good option, particularly in young couples with relatively brief duration of infertility and in those unwilling or unable to pursue more aggressive therapies involving greater costs, risks, and logistic demands. Such treatment is most effective when it is combined with properly timed intrauterine insemination (IUI), all to bring together more than the usual amount of ova and sperm at the optimal time.